Author

J. T. Huse

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 7 Biophysics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 7 Organism:human· 7 Research Focus:cell type annotation· 6 Assay:bulk RNA-seq· 5 Research Focus:differential expression· 5 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell-cell communication· 2 Research Focus:chromatin & epigenetic regulation· 2

Frequent Co-Authors

C. Danussi· 2 shared F. L. Muller· 2 shared J. De Groot· 2 shared J. J. Ackroyd· 2 shared K. Arthur· 2 shared P. B. Malgulwar· 2 shared S. Dharmaiah· 2 shared V. C. Yan· 2 shared

Activity by Year

2018-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

C. Danussi

Mutual co-authors in cluster

Author profile →

8 papers

Recent·Most cited

Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomas

S. Hariharan, B. T. Whitfield, C. J. Pirozzi, M. S. Waitkus, M. C. Brown, M. L. Bowie, D. M. Irvin, K. Roso, R. Fuller, J. Hostettler, S. Dharmaiah, E. A. Gibson, A. Briley, A. Mangoli, C. Fraley, , D. M. Ashley

This study shows that ATRX loss primes glioma cells for innate immune recognition, while IDH1R132H mutation suppresses immune signaling, which can be reversed by IDH1 inhibition.

bioRxiv · Apr 20, 2023 · PreprintCancer Biology

Triggering receptor expressed on myeloid cells 2 (TREM2) regulates phagocytosis in glioblastoma

M. M. Peshoff, P. Gupta, R. Trivedi, S. Oberai, P. Chakrapani, M. Dang, N. K. Milam, M. E. Maynard, B. D. Vaillant, J. T. Huse, L. Wang, K. Clise-Dwyer, K. P. Bhat

This study shows TREM2 promotes phagocytosis in gliomas and is not linked to immunosuppression, suggesting TREM2 activation could enhance immunotherapy for brain tumors.

bioRxiv · Apr 5, 2023Cancer Biology

Sirtuin 2 inhibition modulates chromatin landscapes genome- wide to induce senescence in ATRX-deficient malignant glioma

P. B. Malgulwar, C. Danussi, S. Dharmaiah, W. Johnson, A. Rao, J. T. Huse

This study shows that SIRT2 inhibition induces senescence in ATRX-deficient glioma models by altering chromatin landscapes and transcriptional profiles.

bioRxiv · Jan 9, 2023Cancer Biology

HepaCAM Suppresses Glioblastoma Stem Cell Invasion in the Brain

A. De, J. M. Lattier, J. E. Morales, J. R. Kelly, X. Zheng, Z. Chen, S. Sebastian, J. T. Huse, F. F. Lang, J. H. McCarty

This study shows that hepaCAM suppresses GBM stem cell invasion by balancing ECM adhesion and signaling pathways, suggesting it as a potential therapeutic target.

bioRxiv · Aug 24, 2022 · PreprintCancer Biology

Longitudinal analysis of diffuse glioma reveals cell state dynamics at recurrence associated with changes in genetics and the microenvironment

F. S. Varn, K. C. Johnson, T. E. Wade, T. M. Malta, T. S. Sabedot, F. P. Barthel, H. Kim, N. Ahmed, I. Datta, J. S. Barnholtz-Sloan, S. Bakas, F. D'Angelo, H. K. Gan, L. Garofano, J. T. Huse, , The GLASS Consortium

This study analyzes longitudinal glioma data to identify recurrence-associated changes in genetics and microenvironment linked to therapy resistance.

bioRxiv · May 3, 2021Cancer Biology

Robust detection of oncometabolic aberrations by 1H-13C heteronuclear single quantum correlation in live cells and intact tumors ex-vivo

Y. Barekatain, V. C. Yan, K. Arthur, J. J. Ackroyd, S. Khadka, J. De Groot, J. T. Huse, F. L. Muller

This paper demonstrates that 1H-13C HSQC NMR can detect oncometabolic aberrations in live cells and tumors without specialized equipment, improving sensitivity and resolution over traditional methods.

bioRxiv · Dec 18, 2019Biophysics

Methylthioadenosine is Not Dramatically Elevated in MTAP-Homozygous Deleted Primary Glioblastomas

Y. Barekatain, V. C. Yan, J. J. Ackroyd, A. H. Poral, T. Tran, D. K. Georgiou, K. Arthur, A. deCarvalho, Y.-H. Lin, N. B. Satani, E. S. Ballato, R. Verhaak, J. de Groot, J. T. Huse, J. M. Asara, F. L. Muller

This paper shows that MTA levels are not significantly elevated in MTAP-homozygous deleted primary human glioblastomas, challenging the clinical relevance of targeting PRMT5 and MAT2A in these tumors.

bioRxiv · Oct 18, 2019Cancer Biology

G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant glioma

Y. Wang, J. Yang, W. H. Wu, R. Shah, C. Danussi, G. J. Riggins, K. Kannan, E. P. Sulman, T. A. Chan, J. T. Huse

This study shows ATRX deficiency in glioma causes genomic instability via G-quadruplex DNA, and G4 stabilization can be therapeutically targeted.

bioRxiv · Jun 14, 2018Cancer Biology